UBS Group
CRDF icon

UBS Group’s Cardiff Oncology CRDF Stock Holding History

UBS Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$130K – 10284
2024
Q4 		$130K Buy
+30,000
New +$93.8K ﹤0.01% 6711

Other funds holding CRDF

Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
GoalVest Advisory
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group's CRDF Position: Q3 2026 in Review

UBS Group reduced its Cardiff Oncology (CRDF) stake by 53% in Q3 2026, selling an estimated $363K and leaving 300,156 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #6380.

UBS Group first reported a position in CRDF in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.23M in Q4 2024. 63 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • UBS Group held 300,156 shares of Cardiff Oncology worth $363K as of Q3 2026.
  • UBS Group sold 338,543 Cardiff Oncology shares in Q3 2026, an estimated $363K.
  • Cardiff Oncology made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6380 holding.
  • UBS Group first reported a position in Cardiff Oncology in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Cardiff Oncology position peaked at $1.23M in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.